[go: up one dir, main page]

PL2347775T3 - Rusztowania do przeszczepiania komórek - Google Patents

Rusztowania do przeszczepiania komórek

Info

Publication number
PL2347775T3
PL2347775T3 PL10194565T PL10194565T PL2347775T3 PL 2347775 T3 PL2347775 T3 PL 2347775T3 PL 10194565 T PL10194565 T PL 10194565T PL 10194565 T PL10194565 T PL 10194565T PL 2347775 T3 PL2347775 T3 PL 2347775T3
Authority
PL
Poland
Prior art keywords
composition
scaffolds
cell transplantation
scaffold
bioactive
Prior art date
Application number
PL10194565T
Other languages
English (en)
Inventor
David J. Mooney
Omar Abdel-Rahman Ali
Eduardo Alexandre Barros E Silva
Hyun Joon Kong
Elliott Earl Hill
Tanyarut Boontheekul
Original Assignee
President And Fellows Of Harvard College
Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College, Regents Of The University Of Michigan filed Critical President And Fellows Of Harvard College
Publication of PL2347775T3 publication Critical patent/PL2347775T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3826—Muscle cells, e.g. smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/438—Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/30—Materials or treatment for tissue regeneration for muscle reconstruction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
PL10194565T 2005-12-13 2006-12-13 Rusztowania do przeszczepiania komórek PL2347775T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74999805P 2005-12-13 2005-12-13
US81413406P 2006-06-16 2006-06-16
EP10194565.7A EP2347775B1 (en) 2005-12-13 2006-12-13 Scaffolds for cell transplantation
PCT/US2006/047823 WO2007070660A2 (en) 2005-12-13 2006-12-13 Scaffolds for cell transplantation
EP06847667A EP1960009B1 (en) 2005-12-13 2006-12-13 Scaffolds for cell transplantation

Publications (1)

Publication Number Publication Date
PL2347775T3 true PL2347775T3 (pl) 2020-11-16

Family

ID=38163533

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10194565T PL2347775T3 (pl) 2005-12-13 2006-12-13 Rusztowania do przeszczepiania komórek

Country Status (13)

Country Link
US (8) US8067237B2 (pl)
EP (3) EP2347775B1 (pl)
JP (5) JP5539649B2 (pl)
AT (1) ATE534415T1 (pl)
AU (1) AU2006326405B2 (pl)
CA (1) CA2632630C (pl)
DK (1) DK2347775T3 (pl)
ES (1) ES2804472T3 (pl)
HU (1) HUE051267T2 (pl)
PL (1) PL2347775T3 (pl)
PT (1) PT2347775T (pl)
SI (1) SI2347775T1 (pl)
WO (1) WO2007070660A2 (pl)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086706A2 (en) * 2004-03-05 2005-09-22 The Trustees Of Columbia University In The City Of New York Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
AU2006326405B2 (en) 2005-12-13 2013-10-31 President And Fellows Of Harvard College Scaffolds for cell transplantation
US8198080B2 (en) * 2005-12-14 2012-06-12 The Invention Science Fund I, Llc Bone delivery device
US9005944B2 (en) * 2005-12-14 2015-04-14 The Invention Science Fund I, Llc Bone cell delivery device
US20110182859A1 (en) * 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US9061075B2 (en) * 2005-12-14 2015-06-23 The Invention Science Fund I, Llc Bone delivery device
US8900865B2 (en) * 2005-12-14 2014-12-02 The Invention Science Fund I, Llc Blood brain barrier device
US8354258B2 (en) 2005-12-14 2013-01-15 The Invention Science Fund I, Llc Diatom device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
WO2007103209A2 (en) * 2006-03-01 2007-09-13 Fmc Biopolymer As Gelled composite
US9485917B2 (en) 2006-12-15 2016-11-08 Ecovative Design, LLC Method for producing grown materials and products made thereby
US8753391B2 (en) 2007-02-12 2014-06-17 The Trustees Of Columbia University In The City Of New York Fully synthetic implantable multi-phased scaffold
CA2681461A1 (en) * 2007-04-06 2008-10-16 Caridianbct, Inc. Improved bioreactor surfaces
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
KR100932688B1 (ko) * 2007-07-06 2009-12-21 한국과학기술연구원 인공혈관용 이중막 구조의 튜브형 다공성 스캐폴드 및 그의제조방법
US20090081276A1 (en) * 2007-08-13 2009-03-26 Eben Alsberg Bioresorbable implant composition
JP2009051773A (ja) * 2007-08-27 2009-03-12 Toyobo Co Ltd 細胞接着能を有するｈｓｐ７０ファミリータンパク質
US8221744B2 (en) * 2007-09-19 2012-07-17 Abbott Cardiovascular Systems Inc. Cytocompatible alginate gels
ES2639183T3 (es) 2007-09-19 2017-10-25 The Charles Stark Draper Laboratory, Inc. Estructuras microfluídicas con sección transversal circular
JP5589274B2 (ja) * 2007-10-25 2014-09-17 東レ株式会社 免疫誘導剤
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US20130116799A1 (en) 2008-03-27 2013-05-09 The Cleveland Clinic Foundation Reinforced tissue graft
US20110014153A1 (en) * 2008-03-27 2011-01-20 Kathleen Derwin Reinforced tissue graft
WO2009136173A2 (en) * 2008-05-07 2009-11-12 Ucl Business Plc Biomimetic cell scaffolds
US9012399B2 (en) * 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
EP2313432B1 (en) 2008-06-30 2017-09-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
EP2196196A1 (en) * 2008-12-10 2010-06-16 Medipol S.A. Compound, medicament, vaccine composition and nanocapsules
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
US20150335400A1 (en) * 2009-06-17 2015-11-26 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
JP5750793B2 (ja) * 2009-07-22 2015-07-22 国立大学法人信州大学 Ｅｓ細胞の継代方法及びｅｓ細胞増殖方法
JP5926180B2 (ja) * 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
DK3290061T3 (da) 2009-08-28 2020-07-13 Sernova Corp Fremgangsmåder og anordninger til cellulær transplantation
US9597358B2 (en) * 2010-03-04 2017-03-21 University of Pittsburgh—of the Commonwealth System of Higher Education Bioengineered human corneal stromal tissue
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
WO2011120904A2 (en) 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
US20130202564A1 (en) * 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
EP2558024B1 (en) * 2010-04-12 2017-03-08 The University Of Miami Macroporous bioengineered scaffolds for cell transplantation
US20110269231A1 (en) * 2010-04-22 2011-11-03 Wisconsin Alumni Research Foundation Proteoglycan-binding peptides that modulate stem cell behavior
TWI415638B (zh) * 2010-04-29 2013-11-21 Nat Health Research Institutes Composite material for repairing cartilage tissue and preparation method thereof
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
US20130280318A1 (en) * 2010-07-12 2013-10-24 The Trustees Of Columbia University In The City Of New York Tissue Scaffolds for Controlled Release of Active Agents
US9938501B2 (en) 2010-07-28 2018-04-10 Jointechlabs, Inc. Encapsulated adipose-derived stem cells, methods for preparation and theraputic use
KR102157971B1 (ko) 2010-10-06 2020-09-18 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
KR20140001900A (ko) * 2010-10-18 2014-01-07 선샤인 바이오테크 인크 인간 다분화능 배아 줄기 세포-유사 전구 세포
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6359966B2 (ja) * 2011-04-28 2018-07-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 最小侵襲投与のための注射可能な予成形される肉眼的三次元スキャフォールド
EP3354665B9 (en) 2011-06-02 2022-08-03 Massachusetts Institute of Technology Modified alginates for cell encapsulation and cell therapy
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
FR2979110B1 (fr) * 2011-08-16 2013-09-27 Etat Francais Ministere De La Defense Service De Sante Des Armees Modelisation in vitro des niches medullaires a cellules souches hematopoietiques : un outil pour etudier la regulation de l'hematopoiese, evaluer le potentiel de nichage d'un greffon hematopoietique et tester la pharmaco-toxicologie de medicaments.
JP5876787B2 (ja) * 2011-08-31 2016-03-02 富士フイルム株式会社 細胞移植用細胞構造体および細胞移植用細胞集合体
EP2755632A1 (en) 2011-09-16 2014-07-23 Ferring BV A fast dissolving pharmaceutical composition
JP6018477B2 (ja) * 2011-11-11 2016-11-02 Hoya株式会社 人工骨−軟骨複合体及びその製造方法
CN109125718A (zh) * 2012-01-13 2019-01-04 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
US9861663B2 (en) * 2012-02-23 2018-01-09 Technion Research & Development Foundation Ltd. Ex-vivo vascularized implant composition comprising poly-l-lactic acid, polylactic-co-glycolic-acid and olfactory bulb cells
EP3662896B1 (en) 2012-04-16 2024-02-28 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
AU2013289403B2 (en) * 2012-07-12 2017-05-11 Ferring B.V. Diclofenac formulations
US9884851B2 (en) 2012-10-19 2018-02-06 Massachusetts Institute Of Technology Heterocycle-bisamide inhibitors of scavenger receptor BI
US11883246B2 (en) 2012-11-21 2024-01-30 Trustees Of Boston University Tissue markers and uses thereof
EP2943565B1 (en) 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
WO2014165652A1 (en) * 2013-04-03 2014-10-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Pem layer-by-layer systems for coating substrates to improve bioactivity and biomolecule delivery
WO2014169250A1 (en) * 2013-04-11 2014-10-16 President And Fellows Of Harvard College Prefabricated alginate-drug bandages
WO2014169249A1 (en) 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Methods for host cell homing and dental pulp regeneration
US10098982B2 (en) 2013-11-20 2018-10-16 Drexel University Compositions and methods for macrophage conversion
JP6787789B2 (ja) 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
US20170182209A1 (en) * 2014-06-12 2017-06-29 President And Fellows Of Harvard College Interpenetrating network hydrogels with independently tunable stiffness
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
BR112017000813B1 (pt) * 2014-07-17 2021-03-16 The Regents Of The University Of California sistemas de gel microporoso, usos de uma pluralidade de partículas de microgel em uma solução aquosa e um agente de recozimento, de camadas de sequestrantes covalentemente estabilizados de partículas de microgel, e de um sequestrante covalentemente estabilizado de partículas de microgel com espaços intersticiais, bem como método para a preparação de partículas de microgel
KR102719485B1 (ko) 2014-08-01 2024-10-21 메사추세츠 인스티튜트 오브 테크놀로지 항-섬유 물질 및 응용을 위한 변형된 알기네이트
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN107001478B (zh) 2014-10-14 2022-01-11 诺华股份有限公司 针对pd-l1的抗体分子及其用途
US20160158414A1 (en) * 2014-12-08 2016-06-09 Cormatrix Cardiovascular, Inc. Anisotropic Constructs and Methods for Forming and Using Same for Treating Damaged Biological Tissue
CA3012602A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
CN107405428A (zh) 2015-03-31 2017-11-28 北卡罗来纳-查佩尔山大学 干细胞的递送载体及其用途
TWI741980B (zh) 2015-04-07 2021-10-11 大陸商四川藍光英諾生物科技股份有限公司 一種生物磚及其用途
JP6462897B2 (ja) * 2015-04-07 2019-01-30 レボテック カンパニー，リミティド 細胞ベースの三次元プリンティングのための組成物
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US10537070B2 (en) 2015-04-15 2020-01-21 Ecovative Design Llc Process for the production of mycelial composite surfaces in a roll-to-roll format
DE102015122375A1 (de) 2015-05-29 2016-12-01 Technische Universität Ilmenau Nachbildung einer Stammzellnische eines Organismus sowie Verfahren zu deren Erzeugung
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
JP6741408B2 (ja) * 2015-09-11 2020-08-19 国立大学法人横浜国立大学 細胞包埋ビーズ及びその製造方法
JP6675859B2 (ja) * 2015-10-30 2020-04-08 国立大学法人横浜国立大学 血管網被包細胞包埋ビーズ及びその製造方法、並びに前記血管網被包細胞包埋ビーズを用いた集積体及びその製造方法
NZ742800A (en) 2015-11-01 2019-03-29 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
KR102558416B1 (ko) 2015-11-01 2023-07-24 메사추세츠 인스티튜트 오브 테크놀로지 개선된 특성을 가진 물질
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3400073A4 (en) * 2016-01-07 2019-08-28 The Regents of The University of Michigan IMPLANTABLE FURNITURE TO DETECT METASTATIC BREAST CANCER IN VIVO
EP3190176A1 (en) 2016-01-11 2017-07-12 IMBA-Institut für Molekulare Biotechnologie GmbH Method for tissue culture development on scaffold and differentiated tissue culture
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
ES2953657T3 (es) * 2016-02-12 2023-11-15 Univ Ottawa Estructuras de pared celular descelularizadas de plantas y hongos y su utilización como materiales de andamiaje
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
WO2017156026A1 (en) 2016-03-07 2017-09-14 The Regents Of The University Of California Bioartificial ultrafiltration device and methods related thereto
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
US10730983B2 (en) 2016-06-13 2020-08-04 Massachusetts Institute Of Technology Biocompatible coatings and hydrogels for reducing foreign body response and fibrosis
JP7044330B2 (ja) * 2016-06-17 2022-03-30 国立大学法人横浜国立大学 毛髪再生用細胞包埋ビーズ及びその製造方法、並びに毛髪再生用キット
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
FR3055805B1 (fr) * 2016-09-09 2020-05-15 Assistance Publique - Hopitaux De Paris (Ap-Hp) Biomateriau a usage therapeutique
US11150251B2 (en) 2016-10-07 2021-10-19 Clemson University Research Foundation Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis
CA3044605A1 (en) * 2016-11-22 2018-05-31 Nutech Ventures Personalized cellular biomanufacturing with a closed, miniature cell culture system
JP2020515544A (ja) * 2017-03-25 2020-05-28 ユニバーシティ オブ マイアミ 治療細胞を含む生物学的足場
CA3063847A1 (en) 2017-05-16 2018-11-22 Embody Inc. Biopolymer compositions, scaffolds and devices
US20200181293A1 (en) * 2017-05-17 2020-06-11 Advance Aesthetic Technologies, Inc. Agaroid Structures and Related Methods fo Use and Manufacture
EP3409303A1 (en) * 2017-06-02 2018-12-05 Geistlich Pharma AG Use of a resorbable crosslinked form stable composition for preparing a membrane
WO2018227205A1 (en) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Compositions for inducing an immune response
MX2019014912A (es) * 2017-06-12 2020-08-06 Univ North Carolina Chapel Hill Composiciones de injerto tipo parche para injerto de células.
US11884934B2 (en) 2017-07-21 2024-01-30 Washington University Methods and compositions for T cell activation
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US11565094B2 (en) 2017-10-17 2023-01-31 The Methodist Hospital System Delivery devices
JP7529567B2 (ja) 2017-10-24 2024-08-06 エムボディ インコーポレイテッド 生体高分子足場移植片およびその生成のための方法
US11318231B2 (en) 2017-11-06 2022-05-03 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
EP3746785A4 (en) 2018-02-02 2022-05-11 Wake Forest University Health Sciences, Inc. Organoids related to immunotherapy and methods of preparing and using the same
GB2573327B (en) * 2018-05-03 2021-05-12 Mosa Meat Bv Apparatus and process for production of tissue from cells
US12234478B2 (en) * 2018-05-07 2025-02-25 Reelabs Pvt. Ltd. Method of autologous primary hair follicles preparation in 3D culture
EP3810407B1 (en) 2018-06-04 2025-01-08 Ramot at Tel-Aviv University Ltd. Support medium for 3d printing of biomaterials
WO2020023462A1 (en) * 2018-07-23 2020-01-30 Georgia Tech Research Corporation Synthetic hydrogel carriers for muscle repair
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
JP7269594B2 (ja) * 2018-09-27 2023-05-09 株式会社村田製作所 細胞分離フィルター及び細胞分離方法
EP3866835B1 (en) * 2018-10-19 2024-01-03 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
KR20210093910A (ko) * 2018-11-20 2021-07-28 에코베이티브 디자인 엘엘씨 균사체 스캐폴드의 생성 방법 및 그의 적용
CN113518635A (zh) * 2018-12-17 2021-10-19 哈佛学院院长等 用于调节免疫系统的生物工程化支架及其用途
EP3917756A4 (en) 2019-02-01 2023-05-10 Embody Inc. MICROFLUIDIC EXTRUSION
AU2020274933A1 (en) * 2019-05-15 2021-09-30 Sekisui Chemical Co., Ltd. Cell culturing scaffolding material and cell culturing vessel
CN112089883B (zh) * 2020-09-14 2022-01-04 海南希睿达生物技术有限公司 一种医用冷敷敷料及其制备方法
KR102348467B1 (ko) * 2021-07-14 2022-01-07 주식회사 휴메딕스 Dna 분획물을 포함하는 필러 제조방법 및 이로부터 제조된 필러
WO2023147291A2 (en) * 2022-01-25 2023-08-03 The Board Of Trustees Of The Leland Stanford Junior University Gene editing and delivery of myeloid cells to promote wound healing
EP4479746A1 (en) * 2022-02-15 2024-12-25 The Regents of The University of Michigan Platform for monitoring transplant rejection

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
GB9206504D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges as wound implants
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0921816A4 (en) 1996-03-28 2004-09-22 Whitehead Biomedical Inst CELLS WITH INCREASED OPSONINE CONTENT AND METHOD FOR REGULATING AN IMMUNE RESPONSE TO ANTIQUE
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
AU3214797A (en) 1996-05-28 1998-01-05 Regents Of The University Of Michigan, The Engineering oral tissues
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
AU733716B2 (en) 1996-09-19 2001-05-24 Regents Of The University Of Michigan, The Polymers containing polysaccharides such as alginates or modified alginates
US5863551A (en) 1996-10-16 1999-01-26 Organogel Canada Ltee Implantable polymer hydrogel for therapeutic uses
GB2318577B (en) 1996-10-28 2000-02-02 Johnson & Johnson Medical Solvent dried polysaccharide sponges
GB2323282B (en) 1997-03-17 2001-03-07 Bristol Myers Squibb Co Improvements relating to hygiene and medical products
EP0991705B1 (en) 1997-03-31 2003-09-10 The Regents Of The University Of Michigan Open pore biodegradable matrices
EP1014897B1 (en) 1997-05-30 2008-10-29 Osteobiologics, Inc. Fiber-reinforced, porous, biodegradable implant device
EP1008351B1 (en) 1997-08-21 2006-11-15 Takara Bio Inc. Carcinostatic agents
DE69917224T2 (de) 1998-02-23 2004-09-09 Massachusetts Institute Of Technology, Cambridge Bioabbaubare polymere mit formgedächtnis
BR9908466A (pt) 1998-03-02 2000-12-05 Applied Vaccine Technologies C Proceso para modular a resposta imune, em um mamìfero, a um antìgeno, dispositivo inplantável para modular uma resposta imune a um antìgeno, e, processos para obter células imunes de um mamìfero, para imunização de um mamìfero com um antìgeno, para a produção de hibridomas produzindo anticorpos monoclonais humanos contra um antìgeno pré-selecionado, para transfectar células imunes de um mamìfero com material genético, e para o tratamento ou profilaxia de uma doença ou condição causada por uma resposta imune
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
JP2002511284A (ja) * 1998-04-09 2002-04-16 シャーロット−メクレンバーグ・ホスピタル・オーソリティ 三次元組織の創造
US7427602B1 (en) 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
US7244714B1 (en) 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
FR2780730B1 (fr) 1998-07-01 2000-10-13 Corneal Ind Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
CA2338928A1 (en) 1998-07-30 2000-02-10 Hynda K. Kleinman Thymosin .beta.4 promotes wound repair
WO2000021572A2 (en) 1998-10-09 2000-04-20 The University Of Michigan Hydrogels and water soluble polymeric carriers for drug delivery
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6974698B1 (en) 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
AU2875700A (en) 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
WO2000056375A2 (en) 1999-03-19 2000-09-28 The Regents Of The University Of Michigan Mineralization and cellular patterning on biomaterial surfaces
PT1163019E (pt) 1999-03-25 2007-12-06 Metabolix Inc Dispositivos médicos e aplicações de polímeros de poli-hidroxialcanoato
JP2002542326A (ja) 1999-04-09 2002-12-10 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 多孔性ハイドロゲル製品の製造
AU782297B2 (en) * 1999-06-30 2005-07-14 Ethicon Inc. Porous tissue scaffoldings for the repair or regeneration of tissue
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
WO2001010421A1 (en) 1999-08-06 2001-02-15 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
WO2001035932A2 (en) 1999-11-18 2001-05-25 The Regents Of The University Of Michigan Sustained drug delivery from structural matrices
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6790840B1 (en) 1999-11-26 2004-09-14 The Regents Of The University Of Michigan Reversibly cross-linked hydrogels
US20020098167A1 (en) 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002016557A2 (en) 2000-08-21 2002-02-28 Rice University Tissue engineering scaffolds promoting matrix protein production
EP1315829B1 (en) 2000-09-09 2010-07-28 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6748954B2 (en) 2000-10-27 2004-06-15 The Regents Of The University Of Michigan Drug release from polymer matrices through mechanical stimulation
AU2002212739A1 (en) * 2000-11-14 2002-05-27 Osteogenesis Co., Ltd. Compositions for forming bone or periodontium and injections for forming bone orperiodontium
AU2002218154A1 (en) 2000-11-27 2002-06-03 Jens Christian Jensenius Collectins as adjuvants
US8554940B2 (en) 2001-01-19 2013-10-08 Single Touch Interactive, Inc. System and method for routing media
CA2434320A1 (en) 2001-01-24 2002-08-01 Schering Corporation Chemokines as adjuvants of immune response
US7029697B2 (en) 2001-02-14 2006-04-18 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
JP4215512B2 (ja) 2001-02-26 2009-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非オリゴマー化タンデム蛍光性タンパク質
JP2002263981A (ja) 2001-03-14 2002-09-17 Murata Mach Ltd 板材吸着持ち上げ装置の吸着制御装置
US20020131953A1 (en) 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
US6656488B2 (en) 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
EP1390076A4 (en) * 2001-04-27 2004-12-15 Xcyte Therapies Inc Maturation of antigen-presenting cells with activated cells
US20030118630A1 (en) 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
US6958158B2 (en) 2001-05-11 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
CA2450720A1 (en) 2001-06-13 2002-12-19 Massachusetts Institute Of Technology In vivo bioreactors
US7297343B2 (en) * 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
CA2412012C (en) * 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
WO2003057072A2 (en) 2001-12-31 2003-07-17 Ares Laboratories, Llc Hemostatic compositions and methods for controlling bleeding
US7575759B2 (en) 2002-01-02 2009-08-18 The Regents Of The University Of Michigan Tissue engineering scaffolds
WO2003070291A1 (fr) 2002-02-19 2003-08-28 National Institute Of Advanced Industrial Science And Technology Implant contenant des cellules dans lesquelles on a transfere un gene du facteur de croissance
US20070026518A1 (en) 2005-03-29 2007-02-01 The Regents Of The University Of California Controlling stem cell destiny with tunable matrices
US20080233181A1 (en) 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
US6811777B2 (en) 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
AU2003234159A1 (en) 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
AU2003219383B2 (en) 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
AU2003249606A1 (en) 2002-05-13 2003-12-02 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7332160B2 (en) 2002-07-12 2008-02-19 Boston Scientific Scimed, Inc. Medical device and method for tissue removal and repair
ES2327040T3 (es) 2002-09-12 2009-10-23 Oncotherapy Science, Inc. Peptidos kdr y vacunas que los contienen.
US20040136968A1 (en) * 2002-09-27 2004-07-15 Verigen Ag Autologous cells on a support matrix for tissue repair
US20040063206A1 (en) * 2002-09-30 2004-04-01 Rowley Jon A. Programmable scaffold and method for making and using the same
WO2004030706A2 (en) * 2002-10-01 2004-04-15 Law Peter K Bioactive implants
JP2004159849A (ja) 2002-11-12 2004-06-10 National Institute Of Advanced Industrial & Technology 細胞接着性生体吸収材料、人工血管およびそれらの製造方法
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US8940292B2 (en) 2003-01-28 2015-01-27 Wake Forest University Health Sciences Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
MXPA05011896A (es) 2003-05-05 2006-05-25 Univ Ben Gurion Preparaciones polimericas reticuladas inyectables y sus usos.
EP1475434A1 (en) 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
JP2007528848A (ja) 2003-07-09 2007-10-18 ヴァックスデザイン・コーポレーション ワクチン接種ノードを用いるプログラムされた免疫応答
US20060264380A1 (en) 2003-07-21 2006-11-23 Mats Hellstrom Compounds and Methods for Promoting Angiogenesis
WO2005026318A2 (en) 2003-07-31 2005-03-24 Endacea, Inc. Methods and compositions for producing antigenic responses
GB0317999D0 (en) 2003-07-31 2003-09-03 Univ Liege Improvements in or relating to drug delivery systems
JP5059406B2 (ja) 2003-08-29 2012-10-24 メイヨ フオンデーシヨン フオー メデイカル エジユケーシヨン アンド リサーチ 生分解性スカフォールド類製造用ヒドロゲルポロゲン類
EP2481422A3 (en) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
JP5021309B2 (ja) 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
US8162925B2 (en) 2003-11-07 2012-04-24 Carnegie Mellon University Robot for minimally invasive interventions
CA2448995A1 (en) 2003-11-12 2005-05-12 James Keenan Device and method for attracting diseased cells and foreign substances
JP2005160669A (ja) * 2003-12-02 2005-06-23 Olympus Corp 生体組織補填体の製造方法
JP2005170816A (ja) * 2003-12-09 2005-06-30 Naoki Ishiguro 軟骨修復用材料、およびその製造方法
JP2005168760A (ja) 2003-12-10 2005-06-30 Gunze Ltd 再生医療用支持体、血管再生用支持体、神経再生用支持体及び治療方法
EP1697511A4 (en) 2003-12-11 2007-11-21 Vaxdesign Corp IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US7192693B2 (en) 2004-02-24 2007-03-20 University Of Washington Methods for photopatterning hydrogels
WO2005087238A2 (en) 2004-03-15 2005-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
WO2005104755A2 (en) 2004-04-28 2005-11-10 Vaxdesign Corporation Artificial immune system: methods for making and use
EP1753453A2 (en) 2004-06-08 2007-02-21 Coley Pharmaceutical GmbH Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
WO2007001332A2 (en) 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
CA2589602A1 (en) 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
AU2005295927B2 (en) 2004-10-12 2012-02-02 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
US7999161B2 (en) 2005-01-22 2011-08-16 Alexander Oraevsky Laser-activated nanothermolysis of cells
US7569850B2 (en) 2005-01-24 2009-08-04 Lawrence Livermore National Security, Llc Lipid bilayers on nano-templates
EP1877000B1 (en) 2005-03-23 2012-10-17 Mayo Foundation For Medical Education And Research Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery
EP1712238A1 (en) 2005-04-11 2006-10-18 Institut Gustave Roussy Anthracyclin induced immunogenic dead or dying cells composition
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20070003595A1 (en) 2005-04-19 2007-01-04 Shaopeng Wang Three dimensional micro-environments and methods of making and using same
JP5185813B2 (ja) 2005-04-26 2013-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌免疫治療のための組成物および方法
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
ITPI20050071A1 (it) 2005-06-20 2006-12-21 Giuseppe Calvosa Composizione biocompatibile per la sostituzione/rigenerazione di tessuti
US7645742B2 (en) 2005-06-22 2010-01-12 Advocare International, L.P. Composition for enhancing cellular energy
CN1302050C (zh) 2005-07-07 2007-02-28 复旦大学 一种互穿网络聚合物超多孔水凝胶及其制备方法和应用
WO2007022188A2 (en) 2005-08-15 2007-02-22 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery A porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
US20070081972A1 (en) 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
EP1937812A2 (en) 2005-10-12 2008-07-02 Cancer Research Technology Limited Methods and compositions for treating immune disorders
US8029575B2 (en) 2005-10-25 2011-10-04 Globus Medical, Inc. Porous and nonporous materials for tissue grafting and repair
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
EP2119450B1 (en) 2005-11-29 2013-02-13 Actogenix N.V. Induction of mucosal tolerance to pancreatic islet beta-cell autoantigens
KR100687281B1 (ko) 2005-11-30 2007-02-27 한국과학기술연구원 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법
EP1957044B1 (en) 2005-12-01 2013-03-13 Pronai Therapeutics, Inc. Amphoteric liposome formulation
AU2006326405B2 (en) 2005-12-13 2013-10-31 President And Fellows Of Harvard College Scaffolds for cell transplantation
AU2015264807A1 (en) 2005-12-13 2015-12-17 President And Fellows Of Harvard College Scaffolds for Cell Transplantation
KR101105890B1 (ko) 2005-12-14 2012-01-16 에스씨아이엘 테크놀로지 게엠베하 골 재생을 위한 성형성 생체적응재료
EP1806395A1 (en) 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20070178159A1 (en) 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
CA2676601A1 (en) 2006-01-31 2007-08-09 Medivas, Llc Vaccine delivery compositions and methods of use
US20090041825A1 (en) 2006-02-10 2009-02-12 Kotov Nicholas A Cell culture well-plates having inverted colloidal crystal scaffolds
US20070190646A1 (en) 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
US20100015709A1 (en) 2006-02-10 2010-01-21 Trustees Of The University Of Pennsylvania Regulating Stem Cell Differentiation By Controlling 2D and 3D Matrix Elasticity
WO2007097710A1 (en) 2006-02-27 2007-08-30 Agency For Science, Technology And Research Curable bone cement
US9456860B2 (en) 2006-03-14 2016-10-04 Kci Licensing, Inc. Bioresorbable foaming tissue dressing
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
US20090297579A1 (en) 2006-06-01 2009-12-03 Massachusetts Institute Of Technology Control of Cells and Cell Multipotentiality in Three Dimensional Matrices
US20080138416A1 (en) 2006-06-13 2008-06-12 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
US20070298067A1 (en) 2006-06-22 2007-12-27 Boston Scientific Scimed, Inc. Control release drug coating for medical devices
CA2690973A1 (en) 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
US8535719B2 (en) 2006-07-07 2013-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biohybrid elastomeric scaffolds and methods of use thereof
JP4989934B2 (ja) 2006-07-14 2012-08-01 パナソニック株式会社 スピーカシステム
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
KR100802139B1 (ko) 2006-08-08 2008-02-11 한국생명공학연구원 자성 나노입자를 함유하는 골드 나노케이지
KR100818708B1 (ko) 2006-08-18 2008-04-01 주식회사 하이닉스반도체 표면 세정을 포함하는 반도체소자 제조방법
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
US8084055B2 (en) 2006-09-21 2011-12-27 Purdue Research Foundation Collagen preparation and method of isolation
EP3590503A1 (en) 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
KR20090082468A (ko) 2006-11-09 2009-07-30 케이씨아이 라이센싱 인코포레이티드 상처에 적합한 다공성의 생체흡수성 드레싱 및 그 제조 방법
WO2008086486A1 (en) 2007-01-10 2008-07-17 The Regents Of The University Of Michigan Porous objects having immobilized encapsulated biomolecules
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
US8501905B2 (en) 2007-03-22 2013-08-06 The Regents Of The University Of California Synthetic cell platforms and methods of use thereof
EP1975230A1 (en) 2007-03-30 2008-10-01 Capsulution Nanoscience AG Method for forming glucose sensing micro-particles, use of micro-particles, and kit
WO2008131074A1 (en) 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
AU2008258646A1 (en) 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
US20090136470A1 (en) 2007-06-13 2009-05-28 Hilde Cheroutre Regulatory t cells and methods of making and using same
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
DK2173859T3 (en) 2007-06-29 2016-08-22 Makoto Funaki Soft-gel systems for the modulation of stem cell development
CN102317303A (zh) 2007-07-31 2012-01-11 约翰·霍普金斯大学 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物
GB0716264D0 (en) 2007-08-21 2007-09-26 Isis Innovation Bilayers
US20090192079A1 (en) 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009117721A1 (en) 2008-03-21 2009-09-24 3D Biotek, Llc Hybrid biomedical device fabricated from biomaterials and coated with a cell culture derived ecm coating
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2009155583A1 (en) 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Biomaterials for tissue replacement
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
US8889124B2 (en) 2008-09-25 2014-11-18 The Board Of Trustees Of The Leland Stanford Junior University Tolerogenic populations of dendritic cells
US8940331B2 (en) 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
KR101132732B1 (ko) 2008-11-26 2012-04-06 한국과학기술연구원 인 시튜 조직재생용 지능형 다공성 생분해 고분자 지지체 및 이의 제조방법
US8273373B2 (en) 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
CN107619804A (zh) 2009-01-08 2018-01-23 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
JP2010227012A (ja) 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞捕捉デバイス
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8551749B2 (en) 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
JP5926180B2 (ja) 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
CN101655611B (zh) 2009-09-11 2011-06-08 中国科学院长春应用化学研究所 一种具有双层杂化结构的反蛋白石水凝胶光子晶体的制备方法
JP2013507123A (ja) 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｃ型レクチンドメインをベースとするコンビナトリアルライブラリー
CA2777162A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20110207166A1 (en) 2009-11-06 2011-08-25 Sarah Rivkah Vaiselbuh Human bone marrow microenvironments and uses thereof
WO2011074573A1 (ja) 2009-12-18 2011-06-23 花王株式会社 メソポーラスシリカ粒子の製造方法
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
ES2678143T3 (es) 2010-01-19 2018-08-09 President And Fellows Of Harvard College Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos
BR112012021037A2 (pt) 2010-02-22 2017-06-20 Wikicell Designs Inc sistemas de uma substância comestível ou potável e processo para fabricação de uma composição comestível ou potável envolta em uma membrana
JP5972796B2 (ja) 2010-03-02 2016-08-17 キング アブドゥーラ ユニバーシティ オブ サイエンス アンド テクノロジー 高表面積の繊維状シリカナノ粒子
EP2543636A4 (en) 2010-03-04 2015-12-09 Tokyo Metro Ind Tech Res Inst PREPARATION FOR POROUS SILICON AND POROUS SILICON
US9610328B2 (en) 2010-03-05 2017-04-04 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1
US20130029030A1 (en) 2010-03-15 2013-01-31 Kristian Larsen Method for promotion of hemostasis and/or wound healing
US20110300186A1 (en) 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
US20110256184A1 (en) 2010-04-14 2011-10-20 Battelle Memorial Institute Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
MX352324B (es) 2010-05-26 2017-11-17 Selecta Biosciences Inc Star Vacunas multivalentes de nanovehiculos sinteticos.
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
WO2011163669A2 (en) 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
JP2013531043A (ja) 2010-07-16 2013-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 癌の免疫療法のための方法及び組成物
AU2011285639B2 (en) 2010-08-04 2014-12-18 Georgia Tech Research Corporation Devices, systems, and methods for excavating cancer cells
KR102157971B1 (ko) 2010-10-06 2020-09-18 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US10647959B2 (en) 2011-04-27 2020-05-12 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
JP6359966B2 (ja) 2011-04-28 2018-07-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 最小侵襲投与のための注射可能な予成形される肉眼的三次元スキャフォールド
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012149265A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
AU2012272937B2 (en) 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
US20130145488A1 (en) 2011-12-06 2013-06-06 Iowa State University Research Foundation, Inc. Mesoporous silica nanoparticles suitable for co-delivery
CN109125718A (zh) 2012-01-13 2019-01-04 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
RU2654210C2 (ru) 2012-03-16 2018-05-17 Мерк Патент Гмбх Нацеливающие аминокислотные липиды
EP3662896B1 (en) 2012-04-16 2024-02-28 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
CA3062003C (en) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
WO2013190555A1 (en) 2012-06-21 2013-12-27 Compugen Ltd. Lsr antibodies, and uses thereof for treatment of cancer
US20140072510A1 (en) 2012-09-13 2014-03-13 Northwestern University Synthetic Scaffolds for Metastasis Detection
CN105209074A (zh) 2012-10-20 2015-12-30 得克萨斯大学体系董事会 癌细胞陷阱
WO2014160499A2 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US20160129053A1 (en) 2013-05-24 2016-05-12 President And Fellows Of Harvard College Methods of isolating microorganisms and uses thereof
WO2015066535A1 (en) 2013-11-01 2015-05-07 Yale University Modular particles for immunotherapy
US10821208B2 (en) 2014-04-04 2020-11-03 President And Fellows Of Harvard College Click-crosslinked hydrogels and methods of use
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
US11065362B2 (en) 2014-06-12 2021-07-20 President And Fellows Of Harvard College Viscoelastic hydrogels with fast stress relaxation
US11229607B2 (en) 2014-06-30 2022-01-25 President And Fellows Of Harvard College Hydrogel compositions comprising encapsulated cells and methods of use thereof
CA3012602A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US20180117171A1 (en) 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018026884A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses

Also Published As

Publication number Publication date
US9446107B2 (en) 2016-09-20
JP2017079778A (ja) 2017-05-18
AU2006326405A1 (en) 2007-06-21
US20160279220A1 (en) 2016-09-29
US10137184B2 (en) 2018-11-27
ATE534415T1 (de) 2011-12-15
US20120134967A1 (en) 2012-05-31
US9132210B2 (en) 2015-09-15
WO2007070660A2 (en) 2007-06-21
US20150024026A1 (en) 2015-01-22
JP7065806B2 (ja) 2022-05-12
US10149897B2 (en) 2018-12-11
EP2347775A1 (en) 2011-07-27
SI2347775T1 (sl) 2020-10-30
JP6140222B2 (ja) 2017-05-31
US20190125849A1 (en) 2019-05-02
CA2632630C (en) 2016-12-06
US8067237B2 (en) 2011-11-29
US20160271298A1 (en) 2016-09-22
CA2632630A1 (en) 2007-06-21
US11096997B2 (en) 2021-08-24
US20080044900A1 (en) 2008-02-21
WO2007070660A3 (en) 2008-07-24
WO2007070660A9 (en) 2007-08-02
JP2015226540A (ja) 2015-12-17
DK2347775T3 (da) 2020-07-13
EP2347774A1 (en) 2011-07-27
HUE051267T2 (hu) 2021-03-01
EP2347775B1 (en) 2020-04-15
JP2014057595A (ja) 2014-04-03
ES2804472T3 (es) 2021-02-08
JP2019162145A (ja) 2019-09-26
JP2009519042A (ja) 2009-05-14
AU2006326405B2 (en) 2013-10-31
PT2347775T (pt) 2020-07-14
JP5976622B2 (ja) 2016-08-23
US20150366956A1 (en) 2015-12-24
EP2347774B1 (en) 2017-07-26
EP1960009A2 (en) 2008-08-27
US8932583B2 (en) 2015-01-13
JP6595446B2 (ja) 2019-10-23
EP1960009B1 (en) 2011-11-23
JP5539649B2 (ja) 2014-07-02
US20160279219A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
PT2347775T (pt) Estruturas em andaime para transplante celular
WO2009002401A3 (en) Scaffolds for cell collection or elimination
WO2007145961A3 (en) Microporous coating on medical devices
EP2409707B8 (en) Polymer-based sustained release device
HK1118304A1 (en) Dispersion containing hollow sio2, coating composition, and substrate with antireflection coating film
WO2009048645A3 (en) Lipid coatings for implantable medical devices
WO2009018037A3 (en) Medical devices comprising porous inorganic fibers for the release of therapeutic agents
IL206127A0 (en) Azolylmethyloxiranes, use thereof and agents containing the same
PL2122714T3 (pl) Organiczny/nieorganiczny separator kompozytowy z powłokową porowatą warstwą aktywną i zawierające go urządzenie elektrochemiczne
EP1738425A4 (en) ACTIVE ANODE MATERIAL WITH IMPROVED ELECTROCHEMICAL PROPERTIES AND ELECTROCHEMICAL DEVICE THEREWITH
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
WO2006104976A3 (en) Controlled drug release coating for medical devices
PT1860938E (pt) Composição inseticida aquosa e a sua utilização na proteção de materiais lenhocelulósicos
PL1773918T3 (pl) Środek do dostarczania podłoży na bazie celulozy i/lub skrobi o właściwościach wodoodporności a jednocześnie przeciwgrzybiczych, przeciwbakteryjnych, odstraszających owady i przeciw glonom
EA200801542A1 (ru) Полипропиленовые композиции
WO2008042748A3 (en) Polyelectrolyte media for bioactive agent delivery
TWI346136B (en) Conducting film composition for organic opto-electronic device comprising graft copolymer of self-doped conducting polymer and organic opto-electronic device using the same
DE602006005566D1 (de) Anorganische Beschichtungszusammensetzung, hydrophile Beschichtung und landwirtschaftliche Folie
WO2007092043A3 (en) Bioactive material delivery systems comprising sol-gel compositions
TR200807139A2 (tr) Suda taşinan aerosol bi̇leşi̇mi̇.
GB2432838B (en) Light emitting polymer composition and polymer light emitting device
WO2008134475A3 (en) Implant device release agents and methods of using same
HK1146004A1 (en) Game system, and game device and mission notification device constitute the same
TW200700085A (en) Endoparasiticidal compositions
WO2008104762A3 (en) Bone-replacement materials, methods and devices